Voyager Therapeutics, Inc. (NASDAQ:VYGR) Receives $13.39 Consensus Target Price from Analysts

Shares of Voyager Therapeutics, Inc. (NASDAQ:VYGR - Get Free Report) have earned a consensus rating of "Buy" from the eight research firms that are presently covering the firm, Marketbeat.com reports. Seven equities research analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month price target among analysts that have updated their coverage on the stock in the last year is $13.39.

VYGR has been the topic of several research analyst reports. HC Wainwright reaffirmed a "buy" rating and set a $30.00 target price on shares of Voyager Therapeutics in a research note on Tuesday, April 8th. Wells Fargo & Company set a $10.00 target price on Voyager Therapeutics and gave the company an "overweight" rating in a research note on Wednesday, March 12th. Canaccord Genuity Group lowered their target price on Voyager Therapeutics from $14.00 to $12.00 and set a "buy" rating on the stock in a research note on Thursday, March 13th. Wedbush reaffirmed an "outperform" rating on shares of Voyager Therapeutics in a research note on Wednesday, March 12th. Finally, Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Voyager Therapeutics in a research note on Wednesday, March 12th.

Insider Activity

In other news, CEO Alfred Sandrock sold 10,885 shares of Voyager Therapeutics stock in a transaction dated Wednesday, April 2nd. The stock was sold at an average price of $3.43, for a total transaction of $37,335.55. Following the completion of the sale, the chief executive officer now directly owns 430,931 shares in the company, valued at $1,478,093.33. The trade was a 2.46% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 6.39% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Voyager Therapeutics

Several institutional investors have recently made changes to their positions in VYGR. Vestal Point Capital LP lifted its holdings in shares of Voyager Therapeutics by 151.0% during the 4th quarter. Vestal Point Capital LP now owns 1,230,000 shares of the company's stock valued at $6,974,000 after buying an additional 740,000 shares during the last quarter. AQR Capital Management LLC boosted its position in Voyager Therapeutics by 179.3% during the first quarter. AQR Capital Management LLC now owns 495,260 shares of the company's stock worth $1,674,000 after purchasing an additional 317,927 shares during the period. Farallon Capital Management LLC grew its holdings in Voyager Therapeutics by 12.2% during the fourth quarter. Farallon Capital Management LLC now owns 2,570,700 shares of the company's stock valued at $14,576,000 after purchasing an additional 278,700 shares during the last quarter. Dimensional Fund Advisors LP grew its holdings in Voyager Therapeutics by 24.9% during the fourth quarter. Dimensional Fund Advisors LP now owns 1,380,615 shares of the company's stock valued at $7,828,000 after purchasing an additional 275,571 shares during the last quarter. Finally, Acadian Asset Management LLC raised its position in shares of Voyager Therapeutics by 863.3% in the first quarter. Acadian Asset Management LLC now owns 230,708 shares of the company's stock valued at $778,000 after purchasing an additional 206,758 shares during the period. 48.03% of the stock is currently owned by institutional investors and hedge funds.

Voyager Therapeutics Stock Performance

VYGR traded down $0.25 during trading on Friday, reaching $3.15. The company had a trading volume of 308,449 shares, compared to its average volume of 442,288. The firm's 50-day simple moving average is $3.39 and its 200 day simple moving average is $4.74. The company has a market cap of $174.31 million, a price-to-earnings ratio of 4.44 and a beta of 0.95. Voyager Therapeutics has a 12-month low of $2.75 and a 12-month high of $9.55.

Voyager Therapeutics (NASDAQ:VYGR - Get Free Report) last issued its quarterly earnings results on Tuesday, May 6th. The company reported ($0.53) earnings per share for the quarter, missing analysts' consensus estimates of ($0.35) by ($0.18). The company had revenue of $6.47 million during the quarter, compared to analysts' expectations of $13.55 million. Voyager Therapeutics had a return on equity of 8.33% and a net margin of 15.80%. On average, sell-side analysts expect that Voyager Therapeutics will post -0.91 EPS for the current year.

About Voyager Therapeutics

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.